

Is botulinum toxin the future of orofacial pain management? Evidence and perspectives

Matteo Val^{1,A–D}, Daniele Manfredini^{1,E,F}, Luca Guarda Nardini^{2,A,D}

¹ Department of Biomedical Technologies, School of Dental Medicine, University of Siena, Italy

² Unit of Oral and Maxillofacial Surgery, Ca' Foncello Hospital, Treviso, Italy

A – research concept and design; B – collection and/or assembly of data; C – data analysis and interpretation;

D – writing the article; E – critical revision of the article; F – final approval of the article

Dental and Medical Problems, ISSN 1644-387X (print), ISSN 2300-9020 (online)

Dent Med Probl. 2025;62(3):405–407

Address for correspondence

Matteo Val

E-mail: matteo.val63@gmail.com

Funding sources

None declared

Conflict of interest

None declared

Acknowledgements

None declared

Received on January 11, 2025

Reviewed on January 13, 2025

Accepted on January 15, 2025

Published online on June 24, 2025

Keywords: botulinum toxin, orofacial pain, trigeminal neuralgia, temporomandibular joint disorder

Botulinum toxin (BTX) demonstrates potential as a complementary therapy in managing chronic orofacial pain (OFP), but challenges in the standardization of protocols and indications remain.

The orofacial region is anatomically intricate, housing a dense network of muscles, nerves and blood vessels. This complexity often makes diagnosing and treating orofacial pain (OFP) a challenging endeavor. While OFP is commonly conflated with intraoral pain caused by dental or periodontal pathology, problems with differential diagnosis emerge when it extends to non-odontogenic pain, such as temporomandibular disorder (TMD) or neuropathic pain. Most of these conditions are associated with a high risk for chronicization and impairment, and they often necessitate multidisciplinary approaches for effective management.¹ Amongst the emerging therapies, botulinum toxin (BTX), a neuromodulator known for its cosmetic applications, has gained attention for its potential to manage several pain conditions. The perception is that in several clinical communities, BTX is even emerging as the one-fits-all solution, so questions and concerns about its potential misuse and abuse arise. For this reason, a short recap of the available information supporting its applications, as well as a look at future perspectives, are needed.

Botulinum toxin exerts its effects primarily by inhibiting the release of acetylcholine at neuromuscular junctions, leading to temporary muscle relaxation. This effect is well-known and is the backbone for all applications in cosmetic medicine and dentistry, as well as for claims about its use within the framework of bruxism and/or musculoskeletal pain management. Beyond the modulation of muscle activity, BTX has demonstrated antinociceptive properties by reducing the release of pain mediators, like glutamate, substance P and calcitonin gene-related peptide (CGRP), in sensory neurons. This dual action makes it a promising candidate for managing chronic pain conditions, including those in the orofacial region.² The question is: Has BTX type A (BTX-A) ever done the step from promising to evidence-based treatment?

With regard to the orofacial area, most research has focused on the application of BTX in patients with TMDs and/or bruxism.

Cite as

Val M, Manfredini D, Guarda Nardini L. Is botulinum toxin the future of orofacial pain management? Evidence and perspectives. *Dent Med Probl.* 2025;62(3):405–407. doi:10.17219/dmp/200127

DOI

10.17219/dmp/200127

Copyright

Copyright by Author(s)

This is an article distributed under the terms of the Creative Commons Attribution 3.0 Unported License (CC BY 3.0) (<https://creativecommons.org/licenses/by/3.0/>).

Temporomandibular disorders are the most common source of non-odontogenic OFP, and include disorders of the temporomandibular joint (TMJ), masticatory muscles and related structures. Traditional treatment ranges from physical therapy to oral splints and pharmacological interventions.³ Various studies, including a systematic review by Delcanho et al.,⁴ have highlighted the efficacy of BTX in alleviating pain, improving jaw mobility and enhancing the quality of life (QoL). Patients receiving BTX injections showed significantly reduced pain scores on the visual analog scale (VAS) and improved functional outcomes as compared to the placebo group.⁵ These effects are particularly evident in patients with myogenous TMDs, where muscle hyperactivity is the primary pain source.⁶ Bruxism is a risk factor for muscle fatigue, TMJ pain^{7,8} and dental complications.^{9–11} Consequently, BTX has gained traction as effective treatment for bruxism by reducing masseter and temporalis muscle activity. The same review by Delcanho et al. reported significant decreases in muscle hypertrophy among patients treated with BTX, with minimal adverse effects.⁴ De la Torre Canales et al. also supported that, despite the limited number of studies on this subject, BTX appears to be a feasible management option for bruxism-related symptoms.¹² However, additional research is essential, particularly regarding the specific treatment indications for the reduction of bruxism itself, a target that is often confused with the management of its potential consequences.

Other potential applications vary from neuropathic to neurovascular pain. Botulinum toxin has shown interesting effects in managing conditions like trigeminal neuralgia (TN) and post-herpetic neuralgia (PHN).⁸

Trigeminal neuralgia is severe, electric shock-like pain affecting the trigeminal nerve. Evidence from studies suggests that BTX injections provide substantial pain relief and reduce the frequency of attacks in refractory TN cases, with the benefits sustained for several months post-injection.^{13,14}

Post-herpetic neuralgia is a chronic complication of shingles, and it can cause persistent facial pain. Botulinum toxin has demonstrated efficacy in reducing pain intensity and improving QoL, as highlighted in trials by Xiao et al.¹⁵

As for headaches and migraines, the approval of BTX by the Food and Drug Administration (FDA) for chronic migraine treatment can be seen as a milestone achievement to pave the track for its application in the orofacial region. Chronic migraine, often associated with referred pain in the jaw and neck, responds well to the neuromodulatory activity of BTX.¹¹ Research by Lanteri-Minet et al. showed a significant reduction in the number of headache days and headache intensity, with parallel improvement in associated facial pain.¹⁶

Moreover, preliminary studies suggest that BTX-A significantly reduces referred myofascial pain from the neck muscles, as well as orofacial myofascial pain,

at 2–6 months post-treatment, with no major adverse events reported,¹⁷ and that it might alleviate pain and improve oral function in patients with burning mouth syndrome (BMS).¹⁸

Despite its benefits and encouraging claims, some of the early problems that emerged with BTX therapy are still unchallenged, such as the poor standardization of injection techniques or dosages.¹⁹ Protocols lack uniformity across studies and clinical practices, leading to very different outcomes at the individual level. Also, the high cost and subsequent low accessibility of BTX are impacting its diffusion in the clinical setting and the design of proper investigation in the research setting. The good news is that very few side effects have been reported, although the risk of temporary weakness or facial asymmetry should always be discussed with the candidate patients.

Thus, the role of BTX in OFP management continues to evolve, and future research should prioritize factors such as:

- standardized protocols: Developing evidence-based guidelines for BTX administration in different OFP conditions;
- long-term studies: Assessing the sustainability of therapeutic effects and their impact on patient QoL;
- combined therapies: Exploring BTX as part of multimodal treatment strategies, including physical therapy, pharmacology and cognitive-behavioral interventions²⁰; and
- defined diagnosis: Individualizing the use of BTX in different conditions, with the focus on the psychosocial impairment as an outcome variable.

Additionally, advancement in imaging technologies and biomarker studies may refine patient selection, ensuring personalized and effective BTX treatment.




Fig. 1. Key aspects of botulinum toxin (BTX) in orofacial pain (OFP) management, highlighting applications, challenges and future research directions to improve clinical efficacy and standardization

TMD – temporomandibular disorders.

Botulinum toxin represents a transformative approach in OFP management, offering hope to patients with refractory or chronic conditions (Fig. 1). While not a universal solution, its role as an adjunct therapy is partially supported by scientific evidence. The current problem lies in the lack of development as far as the specific indications and protocols are concerned, which may lead to false claims and clinical misuse. Continued research and innovation are essential to overcome the current limitations and fully integrate BTX into mainstream OFP treatment protocols.

ORCID iDs

Matteo Val  <https://orcid.org/0000-0002-4574-4391>

Daniele Manfredini  <https://orcid.org/0000-0002-4352-3085>

Luca Guarda Nardini  <https://orcid.org/0000-0002-9561-0850>

References

1. International Classification of Orofacial Pain, 1st edition (ICOP). *Cephalalgia*. 2020;40(2):129–221. doi:10.1177/0333102419893823
2. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. *Neurotoxicology*. 2005;26(5):785–793. doi:10.1016/j.neuro.2005.01.017
3. Manfredini D, Häggman-Henrikson B, Al Jaghsi A, et al.; International Network for Orofacial Pain and Related Disorders Methodology. Temporomandibular disorders: INFORM/IADR key points for good clinical practice based on standard of care. *Cranio*. 2025;43(1):1–5. doi:10.1080/08869634.2024.2405298
4. Delcanho R, Val M, Guarda Nardini L, Manfredini D. Botulinum toxin for treating temporomandibular disorders: What is the evidence? *J Oral Facial Pain Headache*. 2022;36(1):6–20. doi:10.11607/ofph.3023
5. Ramos-Herrada RM, Arriola-Guillén LE, Atoche-Socola KJ, Bellini-Pereira SA, Aliaga-Del Castillo A. Effects of botulinum toxin in patients with myofascial pain related to temporomandibular joint disorders: A systematic review. *Dent Med Probl*. 2022;59(2):271–280. doi:10.17219/dmp/145759
6. Guarda Nardini L, Manfredini D, Colonna A, Ferrari Cagidiaco E, Ferrari M, Val M. Intramuscular botulinum toxin as an adjunct to arthrocentesis with viscosupplementation in temporomandibular disorders: A proof-of-concept case–control investigation. *Toxins (Basel)*. 2024;16(8):364. doi:10.3390/toxins16080364
7. Rosati R, Val M, Manfredini D, et al. Baseline masticatory muscles' performance may predict pain relief in temporomandibular disorders. *Oral Dis*. 2024;30(8):5349–5359. doi:10.1111/odi.15011
8. Pentenero M, Val M, Rosso S, Gandolfo S. Microbiopsy a first-level diagnostic test to rule out oral dysplasia or carcinoma in general dental practice. *Oral Dis*. 2018;24(1–2):109–111. doi:10.1111/odi.12735
9. Colonna A, Guarda-Nardini L, Ferrari M, Manfredini D. COVID-19 pandemic and the psyche, bruxism, temporomandibular disorders triangle. *Cranio*. 2024;42(4):429–434. doi:10.1080/08869634.2021.1989768
10. Pollis M, Lobbezoo F, Val M, Ferrari M, Manfredini D. Sleep bruxism and GERD correlation in a general population convenience sample. *Cranio*. 2024;1–7. doi:10.1080/08869634.2024.2443697
11. Cerón L, Pacheco M, Delgado Gaete A, Bravo Torres W, Astudillo Rubio D. Therapies for sleep bruxism in dentistry: A critical evaluation of systematic reviews. *Dent Med Probl*. 2023;60(2):335–344. doi:10.17219/dmp/156400
12. De la Torre Canales G, Câmara-Souza MB, do Amaral CF, Rodrigues Garcia RC, Manfredini D. Is there enough evidence to use botulinum toxin injections for bruxism management? A systematic literature review. *Clin Oral Investig*. 2017;21(3):727–734. doi:10.1007/s00784-017-2092-4
13. Zhang H, Lian Y, Ma Y, et al. Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: Observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. *J Headache Pain*. 2014;15(1):65. doi:10.1186/1129-2377-15-65
14. Chávez-Pérez V, Felipe-Spada N, Roldán-Cubero J, Freire-Nieto P, Tomàs-Aliberas J. Current status of the application of botulinum toxin as a treatment option for trigeminal neuralgia. *Cranio*. 2021;39(1):1–3. doi:10.1080/08869634.2020.1849976
15. Xiao L, Mackey S, Hui H, Xong D, Zhang Q, Zhang D. Subcutaneous injection of botulinum toxin A is beneficial in postherpetic neuralgia. *Pain Med*. 2010;11(12):1827–1833. doi:10.1111/j.1526-4637.2010.01003.x
16. Lanteri-Minet M, Ducros A, Francois C, Olewinska E, Nikodem M, Dupont-Benjamin L. Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data. *Cephalalgia*. 2022;42(14):1543–1564. doi:10.1177/03331024221123058
17. Khalifeh M, Mehta K, Varguise N, Suarez-Durall P, Enciso R. Botulinum toxin type A for the treatment of head and neck chronic myofascial pain syndrome: A systematic review and meta-analysis. *J Am Dent Assoc*. 2016;147(12):959–973.e1. doi:10.1016/j.adaj.2016.08.022
18. Restivo DA, Lauria G, Marchese-Ragona R, Vigneri R. Botulinum toxin for burning mouth syndrome. *Ann Intern Med*. 2017;166(10):762–763. doi:10.7326/L16-0451
19. de Lima MC, Rizzatti Barbosa CM, Duarte Gavião MB, Ferreira Caria PH. Is low dose of botulinum toxin effective in controlling chronic pain in sleep bruxism, awake bruxism, and temporomandibular disorder? *Cranio*. 2024;42(4):421–428. doi:10.1080/08869634.2021.1973215
20. Dadjoo S, Michelogiannakis D, Rossouw PE, Javed F. Potential adjunct therapies for the management of temporomandibular disorders: An evidence-based review. *Cranio*. 2024;42(6):651–661. doi:10.1080/08869634.2022.2036437